Navigation Links
AEterna's acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy

AEterna Laboratories Inc., a biopharmaceutical company focused on the development of novel therapeutic treatments in oncology and endocrinology recently acquired the new German based biopharmaceutical company, Zentaris AG. Following this acquisition// the new entity has in the pipeline six clinical stage products and two preclinical stage products, in oncology and one product already approved and marketed for in vitro fertilization in endocrinology. There are also two products in the preclinical stage and one in the clinical stage, in endocrinology.

AEterna's Chairman and CEO, Dr. Eric Dupont, believes that they now have the right partner to develop a leadership position in two growing therapeutic areas, oncology and endocrinology as Zentaris provides experienced management and drug development teams, an already marketed product, a solid financial position with a positive cash flow for 2002, eight additional global pharmaceutical partnerships and an impressive drug discovery platform.

AEterna's and Zentaris' combined clinical development strategy is based on five factors; development costs, competitive environment, involvement of pharmaceutical partners, time to market and potential markets for future drugs. The new structure is expected to drive drug discovery on an ongoing- forward basis through a state-of-the-art drug discovery unit, including a 100,000 proprietary compound library. Gilles Gagnon, President and COO at AEterna added that given the above five factors and and a portfolio of 12 products in development, the strategy for Neovastat will now strictly focus on the two ongoing Phase III studies in kidney cancer and lung cancer. Results of the kidney cancer trial are expected by the first or second quarter of 2003, while those of the lung cancer trial should be disclosed by the end of 2005.

Prof. Dr. Jurgen Engel, Chief Executive Officer at Zentaris concluded that the combined expertise will allow advancement of multiple pro mising preclinical and clinical projects for the development of novel treatments focused on oncology and endocrinology.


'"/>




Related medicine news :

1. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
2. Are cancer patients being taken for a ride?
3. Nervous disorder being treated
4. Benign eye tumors being treated
5. Heart disease in women being under-treated
6. Chance of water births being urged for mums-to-be
7. CPR! How Effectively is it being done ?
8. Men tend to deny being overweight
9. Yoga, ayurveda being documented to stop patent misuse
10. Surgeons being paid triple the amount to cut waiting lists
11. Fund being raised for treatment to HIV positive Libyan kid
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference ... and Spa in Honolulu, offering local frontline clinicians the opportunity to extend their ... The demand for supplemental training related to pain management has surged dramatically in ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology: